Inflammatory bowel disease

Pediatrics in Review

Volumn 32, Issue 1, 2011, Pages 14-25

  Glick, Sarah R ^a   Carvalho, Ryan S ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PREDNISOLONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ACNE; ANAPHYLAXIS; ARTICLE; BLOODY DIARRHEA; BONE MARROW SUPPRESSION; CATARACT; CHICKENPOX; CLINICAL FEATURE; CROHN DISEASE; CUSHINGOID SYNDROME; DIARRHEA; DIET THERAPY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FOLIC ACID DEFICIENCY; GROWTH DISORDER; HAIR LOSS; HEADACHE; HEPATITIS; HEREDITY; HISTOPLASMOSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILEITIS; INFECTION; INTERSTITIAL NEPHRITIS; LIVER FIBROSIS; LUPUS LIKE SYNDROME; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; OSTEOPENIA; PANCREATITIS; PATHOGENESIS; PNEUMONIA; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PUBERTY DISORDERS; RASH; SERUM SICKNESS; SIDE EFFECT; T CELL LYMPHOMA; TREATMENT INDICATION; TUBERCULOSIS; ULCERATIVE COLITIS; VASCULITIS; VOMITING;

ADOLESCENT; CHILD; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 78651386041     PISSN: 01919601     EISSN: 15263347     Source Type: Journal    
DOI: 10.1542/pir.32-1-14     Document Type: Article

References (69)

1. Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 2006;58:139-157 (Pubitemid 43874878)
2. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143:525-531 (Pubitemid 37352514)
3. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58:1490-1497
4. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995-1000 (Pubitemid 37449406)
5. Weinstein TA, Levine M, Pettei MJ, Gold DM, Kessler BH, Levine JJ. Age and family history at presentation of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2003;37:609-613 (Pubitemid 39280871)
6. Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767-1773 (Pubitemid 36666773)
7. Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol. 2008;14:338-347 (Pubitemid 351320843)
8. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol. 1993;88:356-359
9. Walters TD, Silverberg MS. Genetics of inflammatory bowel disease: current status and future directions. Can J Gastroenterol. 2006;20:633-639 (Pubitemid 44781899)
10. Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut. 2006;55:1114-1123
11. Elson CO. Genes, microbes, and T cells-new therapeutic targets in Crohn's disease. N Engl J Med. 2002;346:614-616
12. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533 (Pubitemid 37328672)
13. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210 (Pubitemid 20288725)
14. Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol. 1997;158:566-573 (Pubitemid 127492631)
15. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205
16. Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut. 1992;33:890-896
17. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol. 1993;39:345-353
18. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:41-62
19. Grand RJ, Homer DR. Approaches to inflammatory bowel disease in childhood and adolescence. Pediatr Clin North Am. 1975;22:835-850
20. Motil KJ, Grand RJ. Ulcerative colitis and Crohn disease in children. Pediatr Rev. 1987;9:109-120
21. Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis, course, and treatment. Gastroenterology. 1977;73:828-832
22. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509-523
23. Palder SB, Shandling B, Bilik R, Griffiths AM, Sherman P. Perianal complications of pediatric Crohn's disease. J Pediatr Surg. 1991;26:513-515
24. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology. 1988;95:1523-1527
25. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289-295
26. Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr. 1994;19:7-21
27. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci. 1986;31:492-497
28. Hyams JMJ, Treem W. Characterization of hepatic abnormalities in children with inflammatory bowel disease. Inflamm Bowel Dis. 1995;1:27
29. Roberts EA. Primary sclerosing cholangitis in children. J Gastroenterol Hepatol. 1999;14:588-593
30. Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology. 1986;91:830-836
31. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119:1113-1119
32. Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414-420 (Pubitemid 350307158)
33. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48-54
34. Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics. 2007;119:e193-e199 (Pubitemid 46397825)
35. Dubinsky MC, Johanson JF, Seidman EG, Ofman JJ. Suspected inflammatory bowel disease-the clinical and economic impact of competing diagnostic strategies. Am J Gastroenterol. 2002;97:2333-2342
36. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758-765 (Pubitemid 32240727)
37. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241 (Pubitemid 39524716)
38. Darbari A, Sena L, Argani P, Oliva-Hemker JM, Thompson R, Cuffari C. Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing pediatric IBD. Inflamm Bowel Dis. 2004;10:67-72 (Pubitemid 38332163)
39. Paolantonio P, Ferrari R, Vecchietti F, Cucchiara S, Laghi A. Current status of MR imaging in the evaluation of IBD in a pediatric population of patients. Eur J Radiol. 2009;69:418-424
40. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-1123
41. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-1129
42. Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004;20(suppl 4):97-101 (Pubitemid 39319256)
43. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473 (Pubitemid 27461232)
44. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990;117:809-814 (Pubitemid 20382623)
45. Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996;22:296-302 (Pubitemid 26098181)
46. Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr. 2009;48:526-530
47. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis. 2006;12:1053-1057 (Pubitemid 44665475)
48. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873
49. Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009;104:3042-3049
50. Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007;44:185-191 (Pubitemid 46175070)
51. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology. 1995;108:1056-1067
52. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982;83:383-387 (Pubitemid 12078222)
53. Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004;127:1809-1814
54. Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49:400-404
55. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443
56. Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Diagnosis and treatment of pouchitis. Best Pract Res Clin Gastroenterol. 2003;17:75-87
57. Gionchetti P, Morselli C, Rizzello F, et al. Management of pouch dysfunction or pouchitis with an ileoanal pouch. Best Pract Res Clin Gastroenterol. 2004;18:993-1006 (Pubitemid 39378184)
58. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40:220-222 (Pubitemid 40269746)
59. Koivusalo A, Pakarinen MP, Rintala RJ. Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Surg. 2007;42:290-295 (Pubitemid 46161547)
60. Stavlo PL, Libsch KD, Rodeberg DA, Moir CR. Pediatric ileal pouch-anal anastomosis: functional outcomes and quality of life. J Pediatr Surg. 2003;38:935-939 (Pubitemid 36666294)
61. Tilney HS, Constantinides V, Ioannides AS, Tekkis PP, Darzi AW, Haddad MJ. Pouch-anal anastomosis vs straight ileoanal anastomosis in pediatric patients: a meta-analysis. J Pediatr Surg. 2006;41:1799-1808 (Pubitemid 44709066)
62. Greenstein AJ, Zhang LP, Miller AT, et al. Relationship of the number of Crohn's strictures and strictureplasties to postoperative recurrence. J Am Coll Surg. 2009;208:1065-1070
63. McLeod RS, Wolff BG, Steinhart AH, et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology. 1997;113:1823-1827
64. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674
65. Sheth SG, LaMont JT. Toxic megacolon. Lancet. 1998;351:509-513
66. Brostrom O, Lofberg R, Nordenvall B, Ost A, Hellers G. The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol. 1987;22:1193-1199 (Pubitemid 18031891)
67. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics. 2006;118:124-129 (Pubitemid 46071155)
68. Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2003;5:225-232 (Pubitemid 38915038)
69. Sylvester FA. IBD and skeletal health: children are not small adults! Inflamm Bowel Dis. 2005;11:1020-1023